QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.51 Million SEK | 1.79% |
| 2022 | -15.79 Million SEK | 10.1% |
| 2021 | -17.56 Million SEK | 29.54% |
| 2020 | -24.93 Million SEK | -38.12% |
| 2019 | -18.05 Million SEK | -56.96% |
| 2018 | -11.5 Million SEK | -196.67% |
| 2017 | -3.87 Million SEK | -303.43% |
| 2016 | -961 Thousand SEK | -209.2% |
| 2015 | 880 Thousand SEK | 187.22% |
| 2014 | -1 Million SEK | 30.51% |
| 2013 | -1.45 Million SEK | 47.71% |
| 2012 | -2.77 Million SEK | -567.51% |
| 2011 | 594 Thousand SEK | -49.58% |
| 2010 | 1.17 Million SEK | 0.6% |
| 2009 | 1.17 Million SEK | 338.58% |
| 2008 | 267 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.53 Million SEK | 0.0% |
| 2024 Q1 | -3.53 Million SEK | -8.67% |
| 2023 Q4 | -3.25 Million SEK | 0.0% |
| 2023 Q1 | -4.5 Million SEK | -20.22% |
| 2023 FY | -15.5 Million SEK | 1.8% |
| 2023 Q2 | -4.5 Million SEK | 0.0% |
| 2023 Q3 | -3.25 Million SEK | 27.82% |
| 2022 FY | -15.79 Million SEK | 10.1% |
| 2022 Q1 | -4.78 Million SEK | 24.87% |
| 2022 Q2 | -4.06 Million SEK | 15.11% |
| 2022 Q4 | -3.74 Million SEK | -17.17% |
| 2022 Q3 | -3.19 Million SEK | 21.29% |
| 2021 Q2 | -3.85 Million SEK | -18.21% |
| 2021 FY | -17.56 Million SEK | 29.54% |
| 2021 Q4 | -6.37 Million SEK | -56.13% |
| 2021 Q1 | -3.26 Million SEK | 46.69% |
| 2021 Q3 | -4.08 Million SEK | -5.81% |
| 2020 Q3 | -8.76 Million SEK | -78.48% |
| 2020 Q2 | -4.9 Million SEK | 4.62% |
| 2020 FY | -24.93 Million SEK | -38.12% |
| 2020 Q1 | -5.14 Million SEK | 0.83% |
| 2020 Q4 | -6.11 Million SEK | 30.15% |
| 2019 FY | -18.05 Million SEK | -56.96% |
| 2019 Q2 | -3.77 Million SEK | -34.58% |
| 2019 Q1 | -2.8 Million SEK | 52.4% |
| 2019 Q4 | -5.18 Million SEK | 17.52% |
| 2019 Q3 | -6.29 Million SEK | -66.83% |
| 2018 Q1 | -1 Million SEK | 4.27% |
| 2018 FY | -11.5 Million SEK | -196.67% |
| 2018 Q4 | -5.88 Million SEK | -300.68% |
| 2018 Q3 | -1.46 Million SEK | 53.19% |
| 2018 Q2 | -3.13 Million SEK | -211.0% |
| 2017 FY | -3.87 Million SEK | -303.43% |
| 2017 Q2 | -1.65 Million SEK | -255.25% |
| 2017 Q3 | -697 Thousand SEK | 57.99% |
| 2017 Q4 | -1.05 Million SEK | -51.22% |
| 2017 Q1 | -467 Thousand SEK | -109.42% |
| 2016 Q1 | -714 Thousand SEK | -80.76% |
| 2016 FY | -961 Thousand SEK | -209.2% |
| 2016 Q3 | -48 Thousand SEK | -300.0% |
| 2016 Q4 | -223 Thousand SEK | -364.58% |
| 2016 Q2 | 24 Thousand SEK | 103.36% |
| 2015 Q1 | 1.13 Million SEK | 228.44% |
| 2015 Q2 | 392 Thousand SEK | -65.55% |
| 2015 Q4 | -395 Thousand SEK | -54.9% |
| 2015 FY | 880 Thousand SEK | 187.22% |
| 2015 Q3 | -255 Thousand SEK | -165.05% |
| 2014 Q1 | 3.25 Million SEK | 127.66% |
| 2014 FY | -1 Million SEK | 30.51% |
| 2014 Q4 | -886 Thousand SEK | -411.97% |
| 2014 Q3 | 284 Thousand SEK | 105.41% |
| 2014 Q2 | -5.25 Million SEK | -261.37% |
| 2013 FY | -1.45 Million SEK | 47.71% |
| 2013 Q4 | -11.76 Million SEK | -204.41% |
| 2013 Q1 | 2.9 Million SEK | 204.72% |
| 2013 Q2 | -3.86 Million SEK | -232.84% |
| 2013 Q3 | 11.26 Million SEK | 391.64% |
| 2012 Q3 | -425 Thousand SEK | 0.0% |
| 2012 Q4 | -2.77 Million SEK | -553.41% |
| 2012 FY | -2.77 Million SEK | -567.51% |
| 2011 Q2 | 694 Thousand SEK | 0.0% |
| 2011 FY | 594 Thousand SEK | -49.58% |
| 2010 Q2 | 657 Thousand SEK | 0.0% |
| 2010 FY | 1.17 Million SEK | 0.6% |
| 2009 Q2 | -117 Thousand SEK | 0.0% |
| 2009 FY | 1.17 Million SEK | 338.58% |
| 2008 FY | 267 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 93.77% |
| Ziccum AB (publ) | -21.56 Million SEK | 28.052% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 5.42% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.14% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1735.74% |
| Mendus AB (publ) | -100.65 Million SEK | 84.588% |
| Genovis AB (publ.) | 54.22 Million SEK | 128.607% |
| Intervacc AB (publ) | -93.57 Million SEK | 83.424% |
| Active Biotech AB (publ) | -46.48 Million SEK | 66.629% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 186.135% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 72.009% |
| Aptahem AB (publ) | -10.1 Million SEK | -53.512% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 95.175% |
| Kancera AB (publ) | -65.04 Million SEK | 76.151% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 88.477% |
| Fluicell AB (publ) | -26.87 Million SEK | 42.29% |
| Saniona AB (publ) | -81.06 Million SEK | 80.865% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -25.39% |
| Biovica International AB (publ) | -126.07 Million SEK | 87.696% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 63.505% |
| AcouSort AB (publ) | -17.48 Million SEK | 11.294% |
| Xintela AB (publ) | -57.23 Million SEK | 72.899% |
| Abliva AB (publ) | -96.54 Million SEK | 83.933% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 95.224% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -342.568% |
| OncoZenge AB (publ) | -15.9 Million SEK | 2.453% |
| Amniotics AB (publ) | -29.07 Million SEK | 46.645% |
| 2cureX AB (publ) | -36.36 Million SEK | 57.341% |
| CombiGene AB (publ) | -36.3 Million SEK | 57.273% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -5.956% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.965% |
| Camurus AB (publ) | 532.35 Million SEK | 102.914% |
| Corline Biomedical AB | -1.78 Million SEK | -767.562% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 91.419% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 62.786% |
| I-Tech AB | 24.43 Million SEK | 163.483% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 98.033% |
| Cyxone AB (publ) | -21.66 Million SEK | 28.387% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 85.361% |
| Biosergen AB | -27.26 Million SEK | 43.107% |
| Cantargia AB (publ) | -290.01 Million SEK | 94.651% |
| NextCell Pharma AB | -43.17 Million SEK | 64.069% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 91.419% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 9.267% |
| Nanologica AB (publ) | -69.96 Million SEK | 77.828% |
| SynAct Pharma AB | -224.49 Million SEK | 93.09% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 64.886% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 35.243% |
| LIDDS AB (publ) | -40.67 Million SEK | 61.863% |
| Lipum AB (publ) | -37.25 Million SEK | 58.362% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.807% |
| Alzinova AB (publ) | -16.52 Million SEK | 6.113% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.88% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -142.631% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 86.52% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 22.975% |
| Simris Alg AB (publ) | -36.63 Million SEK | 57.658% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 89.416% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 95.003% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 86.014% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -34.117% |